Mouse Genome Informatics
tg
    Tg(PDGFB-APPSwInd)20Lms/0
involves: C57BL/6 * DBA/2
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
       
mortality/aging
• high rate of premature (6 months or earlier) death (J:87150)
• mice show premature death of unclear etiology with >15% mortality exhibited by 6 months, compared to all other genotypes (J:121330)

behavior/neurological
• mice are abnormally sensitive to pentylenetetrazole (PTZ)-induced seizures with 20% suffering fatal status epilepticus at a PTZ dose not lethal in non-transgenic controls
• mice exhibit disinhibition-like behaviors in an elevated plus maze compared with wild-type mice
• at 4-7 months of age, mice transgenic mice with wild-type Mapt expression take longer to locate the platform in the cued version of the Morris water maze test compared to transgenic mice heterozygous or homozygous for Mapt deletion
• in the hidden platform version of the Morris water maze, non-trangenic controls, regardless of Mapt genotype learn the task over 3 days, whereas transgenic mice with wild-type expression of Mapt show no evidence of learning (J:121330)
• in probe trials where the platform is removed, mice show no learning, displaying no significantly elevated crossings of the target quadrant after 5 days of training (J:121330)
• in a Morris water maze, mice fail to favor the target platform location unlike wild-type mice (J:141084)
• mice show hyperactivity in the Y-maze, a new cage, and elevated-plus maze compared to other transgenic mice or non-transgenic controls; this persists in mice 12-16 months of age (J:121330)

nervous system
• mice are abnormally sensitive to pentylenetetrazole (PTZ)-induced seizures with 20% suffering fatal status epilepticus at a PTZ dose not lethal in non-transgenic controls
• mice show neuritic dystrophy around amyloid plaques
• aberrant sprouting of hippocampal axons is observed in transgenic mice
• diffuse immunoreactive amyloid deposits detected in dentate gyrus and neocortex of mice aged 5 to 7 months old (J:62290)
• all mice exhibit plaques by age 8 to 10 months (J:62290)
• soluble and insoluble Abeta-40 and -42 peptide deposits at 6-10 months (J:87150)
• at 4-7 months and 14-18 months, Abeta plaque deposition is observed, at levels the same as other transgenics heterozygous null for Mapt (J:121330)
• neurodegeneration is indicated by an age dependent decrease in density of synaptophysin-immunoreactive presynaptic terminals

other phenotype
• diffuse immunoreactive amyloid deposits detected in dentate gyrus and neocortex of mice aged 5 to 7 months old (J:62290)
• all mice exhibit plaques by age 8 to 10 months (J:62290)
• soluble and insoluble Abeta-40 and -42 peptide deposits at 6-10 months (J:87150)
• at 4-7 months and 14-18 months, Abeta plaque deposition is observed, at levels the same as other transgenics heterozygous null for Mapt (J:121330)

cellular
• aberrant sprouting of hippocampal axons is observed in transgenic mice

Mouse Models of Human Disease
OMIM IDRef(s)
Alzheimer Disease; AD 104300 J:62290